100
Participants
Start Date
April 1, 2023
Primary Completion Date
April 1, 2026
Study Completion Date
May 1, 2026
"Venarus® (diosmin and hesperidin)"
"Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months"
Endovenous laser ablation (EVLA) with miniphlebectomy
Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.
Elastic compression
All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment
Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment
RyazanSMU, Ryazan
Ryazan State Medical University
OTHER